Table 3.

Severity grading of peripheral edema (CTCAE term: edema limb) and recommended capmatinib dosage modification

Gradea	CTCAE v5.0 definition [20]	Recommended dose modification [1]
1	5–10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection	No modification
2	> 10–30% inter-limb discrepancy in volume or circumference at point of greatest visible difference; readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental ADL	No modification. If intolerable, consider stopping capmatinib treatment until edema is improved, then resume capmatinib at a reduced dose
3	> 30% inter-limb discrepancy in volume; gross deviation from normal anatomic contour; limiting self-care ADL	Stop capmatinib treatment until edema is improved, then resume capmatinib at a reduced dose

^aThere is no Grade 4 category for edema limb. Adapted with permission from Goodwin et al. [45]

ADL activities of daily living, CTCAE Common Terminology Criteria for Adverse Events